Q2 FY2026 EarningsQ2 FY26 results beat consensus on the top line but missed on bottom-line GAAP metrics: revenue reached $31.7M vs. $27.5M expected, driven by strong U.S. IBTROZI product sales ($23.2M). GAAP EPS was -$0.18 vs. -$0.18 expected, while Normalized EPS hit the -$0.12 mean estimate. A significant $9.5M loss on debt extinguishment and rising non-cash interest from the Sagard agreement weighed on GAAP net income, overshadowing the revenue beat.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Nuvation Bio(NUVB) the Revenue is 31.69 M (+555.6%), Beat estimate;the EBIT is -51.04 M (+19.74%), Beat estimate;the EPS is -0.18 (-5.88%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B555.64%
0.03B468.48%
+0.00B87.16%
EBITExceed expectations
-0.05B19.74%
-0.05B18.67%
+0.00B1.07%
EPSExceed expectations
-0.185.88%
-0.18478.66%
+0.00472.78%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf